{"filing":{"accession_number":"0001628280-26-061834","cik":"0001855175","ticker":"CTNM","company_name":"Contineum Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"ctnm-20260914.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1855175/000162828026061834/ctnm-20260914.htm"},"events":[{"id":33264,"run_id":30585,"accession_number":"0001628280-26-061834","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Contineum disclosed that the MOONLIGHT-1 Phase 2 clinical trial for JNJ-5120/PIPE-307 \"did not meet its primary efficacy endpoint,\" a material negative development for a clinical-stage biopharmaceutical company heavily dependent on pipeline success. While this is a clinical trial result, it does not fit the earnings_release category (which typically covers financial results) nor any other specific taxonomy type; it is a material operational/strategic event affecting the company's drug development prospects that warrants disclosure under Item 8.01.","company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36660,"accession_number":"0001628280-26-061834","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Contineum disclosed that the MOONLIGHT-1 Phase 2 clinical trial for JNJ-5120/PIPE-307 \"did not meet its primary efficacy endpoint,\" a material negative development for a clinical-stage biopharmaceutical company heavily dependent on pipeline success. While this is a clinical trial result, it does not fit the earnings_release category (which typically covers financial results) nor any other specific taxonomy type; it is a material operational/strategic event affecting the company's drug development prospects that warrants disclosure under Item 8.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:09:04.820084+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36660,"accession_number":"0001628280-26-061834","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Contineum disclosed that the MOONLIGHT-1 Phase 2 clinical trial for JNJ-5120/PIPE-307 \"did not meet its primary efficacy endpoint,\" a material negative development for a clinical-stage biopharmaceutical company heavily dependent on pipeline success. While this is a clinical trial result, it does not fit the earnings_release category (which typically covers financial results) nor any other specific taxonomy type; it is a material operational/strategic event affecting the company's drug development prospects that warrants disclosure under Item 8.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:09:04.820084+00:00","company_name":"Contineum Therapeutics, Inc.","ticker":"CTNM","filing_date":"2026-09-14"}]}